GUTS
FRACTYL HEALTH, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.59
−0.80%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.59
From 52W high−75.27%
Volume562130.00
Market cap$93.30M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$0.59
From 52W high
−75.27%
Volume
562130.00
Market cap
$93.30M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.0x
P/E (TTM)
—
RSI (14)
37.4
MomentumView details →
1D Return
−0.80%
YTD Return
−73.29%
SummaryUpdated Jun 1, 2026
Fractyl Health, Inc. (NASDAQ:GUTS) is a metabolic therapeutics company founded in 2010 and based in Lexington, Massachusetts. The company was formerly known as Fractyl Laboratories Inc. before changing its name in June 2021. Fractyl went public on NASDAQ in 2024, focusing on developing innovative therapies for type 2 diabetes and obesity. The company operates two main therapeutic platforms: the Revita procedural therapy system and the Rejuva gene therapy platform, both targeting the growing global epidemic of metabolic diseases.
Similar companies
Latest newsMore news →
SueWallSt reminded shareholders of an October 20, 2026 lead plaintiff deadline in the securities class action lawsuit against Fractyl Health, Inc. (GUTS), in which CEO Harith Rajagopalan and former CFO Lisa A. Davidson face Section 20(a) control person claims over allegedly overstated Revita DMR efficacy data.5d agoA class action lawsuit was filed against Fractyl Health, Inc. on behalf of investors who purchased securities between January 13, 2025 and January 29, 2026.17d agoGlancy Prongay Wolke & Rotter LLP announced a securities fraud lawsuit on behalf of Fractyl Health, Inc. shareholders who suffered losses, related to the company's disclosure of REMAIN-1 Midpoint Cohort data on January 29, 2026.19d ago